Evidence map›Paper›PMID 39411309›Full record

ArticleFrontiers in endocrinology2024

Clinical perspective on innovative insulin delivery technologies in diabetes management.

Güvenç Koçkaya, Tadej Battelino, Goran Petrovski, Johan Jendle, Beatrix Sármán, Nancy Elbarbary, Damla Gökşen, Mohammed Alharbi, Birol Tibet, Amir Mustapha Sharaf and 3 more

Abstract read
In one paragraph

Article in Frontiers in endocrinology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Güvenç KoçkayaDepartment of Health Economics and Outcome Research, ECONiX Research, Samsun, Türkiye.
Tadej BattelinoDepartment of Pediatric and Adolescent Endocrinology, University Medical Center Ljubljana, Ljubljana, Slovenia.
Goran PetrovskiSidra Medicine, Weill Cornell, Ar-Rayyan, Qatar.
Johan JendleMedical Sciences, Örebro University, Örebro, Sweden.
Beatrix SármánDepartment of Medicine, Faculty of Medicine Budapest Hungary, Semmelweis University, Budapest, Hungary.
Nancy ElbarbaryDepartment of Pediatrics, Ain Shams University, Cairo, Egypt.
Damla GökşenDepartment of Pediatrics, Faculty of Medicine, Ege University, Bayraklı, İzmir, Türkiye.
Mohammed AlharbiDeparment of Information Secuity Operation, Ministry of Health Saudi Arabia, Riyadh, Saudi Arabia.
Birol TibetDepartment of Health Economics and Outcome Research, ECONiX Research, Samsun, Türkiye.
Amir Mustapha SharafHealth Economics and Outcomes Research, ECONiX Research, Tunis, Tunisia.
Selin ÖkçünDepartment of Health Economics and Outcome Research, ECONiX Research, Samsun, Türkiye.
Filiz ÖztürkDepartment of Health Economics and Outcome Research, ECONiX Research, Samsun, Türkiye.
Mustafa KurnazDepartment of Health Economics and Outcome Research, ECONiX Research, Samsun, Türkiye.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The primary objective of this study is to report the results of an online questionnaire and the in-person discussion sessions of physicians specializing in diabetes care in which their opinions about current diabetes management was obtained. Methods: The Diabetes Innovation Summit 2023 drew attendance from a diverse group of specialized physicians from multiple countries. A comprehensive literature review was conducted to examine the technologies and medical needs associated with diabetes management. Using the results of the review, a questionnaire was developed by three experts from the steering committee to solicit feedback from specialized physicians. The online survey was made accessible between 10th December 2022 and 10th January 2023. Following the online survey, six structured in-person discussion sessions were conducted with specialized physicians from the Middle East, Central-Eastern Europe, and North Africa regions. Results: The study revealed that about 59% of survey requests were answered, with many participants being pediatric endocrinologists from North Africa. Around 60% of diabetes patients followed Multiple Daily Injections (MDI) according to specialized physicians. Among MDI users, 62% employed Blood Glucose Monitors (BGM), 31% used intermittent-scanning Continuous Glucose Monitors (isCGM), and 23% used CGM. In North Africa, nearly 90% of patients used MDI due to financial constraints. While physicians focused on both Time in Range (TIR) and HbA1c for MDI-treated patients, satisfaction with TIR achieved was expressed by 31%, while 74·1% believed Real-Time CGM (rtCGM) was effective. Concerns arose about potentially misleading HbA1c results and the relatively low patient achievement of target TIR despite CGM usage. The Smart MDI System was seen favorably compared to other applications. The system's affordability was a significant barrier, particularly in the Middle East and Africa. Conclusion: The present study highlights that physicians are generally supportive of utilizing new technology. The questionnaires and the open discussion revealed the expectation that the Smart MDI technology provides better control, primarily by identifying missed boluses, while expressing concerns on the use of the technology by teenagers and children, who might forget the device and be reluctant to use in public, and by the older population, who might be challenged by the technology.

Indexed as

Diabetes MellitusHypoglycemic AgentsInsulinInsulin Infusion SystemsBlood GlucoseBlood Glucose Self-MonitoringDiabetes Mellitus, Type 1Disease ManagementHumansSurveys and QuestionnairesBlood GlucoseHypoglycemic AgentsInsulincontinuous glucose monitor (CGM)diabetes managementdiabetes mellitusmultiple daily injections (MDI)new technologiessmart insulin pens

Identifiers

PMID39411309
PMCPMC11473347

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.